Global Healthcare Analyst

Tina Banerjee

Equity Capital Markets

Meihua International Medical Technologies / Equity Capital Markets

Meihua International Medical Technologies

<ul>
<li>China-Based medical devices company, Meihua International Medical Technologies intends to raise $50 million from its U.S. IPO by offering 5 million shares at price between $9 and $11 per share.</li>
<li>Upon the completion of this offering, the company will have 25 million shares outstanding. At the midpoint of offer price, Meihua will command a market capitalization of $250 million.</li>
<li>Despite attractive valuation, investors can avoid the IPO due to its unimpressive financial performance and concerns over Chinese companies listing in the U.S. market.  </li>
</ul>


China-Based medical devices company, Meihua International Medical Technologies intends to raise $50 million from its U.S. IPO by offering 5 million shares at price between $9 and $11 per share.
Upon the completion of this offering, the company will have 25 million shares outstanding. At the midpoint of offer price, Meihua will command a market capitalization of $250 million.
Despite attractive valuation, investors can avoid the IPO due to its unimpressive financial performance and concerns over Chinese companies listing in the U.S. market.  


Meihua International Medical Technologies Pre-IPO: Risks Overshadow Cheap Valuation

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

<p>On January 20<sup>th</sup>, 2021, <a href="https://www.smartkarma.com/entities/adagene-inc" target="_blank" data-smartkarma-citation="entities:31371:1" rel="noopener">Adagene Inc (ADAG US)</a> filed with the U.S. Securities and Exchange Commission (SEC) to go public, officially starting the process of IPO in the United States. It is said that Adagene may raise as much as $125 million. Meanwhile, according to some media’s reports, Adagene has close ties with the CRO/CDMO giant WuXi AppTec, who is also one of the investors in the Company with 10.8% shares and provides strong support for its IPO. The following mainly provide analysis in terms of platform, pipeline and financial position.</p>

On January 20th, 2021, Adagene Inc (ADAG US) filed with the U.S. Securities and Exchange Commission (SEC) to go public, officially starting the process of IPO in the United States. It is said that Adagene may raise as much as $125 million. Meanwhile, according to some media’s reports, Adagene has close ties with the CRO/CDMO giant WuXi AppTec, who is also one of the investors in the Company with 10.8% shares and provides strong support for its IPO. The following mainly provide analysis in terms of platform, pipeline and financial position.

Pre-IPO Adagene Inc (ADAG US) - Advanced Technology but Still Take Time for Commercialization

China

Adagene Inc. operates as a biotechnology company. The Company focuses on the development of antibodies to cancer patients. Adagene serves patients in the United States and China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Adagene Inc (ADAG US)

Meihua International Medical Technologies Pre-IPO: Risks Overshadow Cheap Valuation

Meihua plans to raise $50 million by offering 5 million shares. At midpoint, the company would command a market cap of $250 million. Shares are...

Tina Banerjee

Pre-IPO Adagene Inc (ADAG US) - Advanced Technology but Still Take Time for Commercialization

This article analyzed Adagene Inc. in terms of the DPL platform, the core products in the pipeline (ADG106, ADG126 and ADG116), the financial...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)